Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 20, 2021, by Harrow Health, Inc. (the "Company"), a Delaware corporation. The report discloses the entry into a material definitive agreement and the creation of a direct financial obligation related to a debt offering that closed on April 20, 2021.
Key Financial Metrics and Transaction Details
The Company completed an offering of senior notes with the following terms:
- Instrument: 8.625% Senior Notes due 2026.
- Principal Amount: $50,000,000 (Firm Notes) plus an option for up to an additional $5,000,000 (Additional Notes).
- Interest Rate: 8.625% per annum, payable quarterly in arrears (first payment July 31, 2021).
- Maturity Date: April 30, 2026.
- Underwriter: B. Riley Securities, Inc.
- Trustee: U.S. Bank National Association.
The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period, as this is a transactional filing rather than a periodic financial report.
Material Changes and Debt Structure
The primary material change is the incurrence of new senior unsecured indebtedness. The Notes rank equally with all existing and future senior unsecured indebtedness. They are effectively subordinated to all secured indebtedness and structurally subordinated to all indebtedness of the Company's subsidiaries.
Redemption, Risks, and Covenants
- Redemption: Prior to February 1, 2026, the Company may redeem the Notes at 100% of principal plus a make-whole premium. On or after February 1, 2026, the Company may redeem them at 100% of principal plus accrued interest.
- Events of Default: Includes bankruptcy, insolvency, or reorganization, which would cause the Notes to become immediately due and payable. Other defaults allow the Trustee or holders of at least 25% of the principal to declare the Notes due.
- Use of Proceeds: The filing text does not explicitly state the intended use of proceeds in the summary sections provided.
Investor Verification Checklist
- Verify the final amount of the "Additional Notes" purchased under the option, if any, by reviewing the Closing Press Release (Exhibit 99.2).
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants, representations, and indemnification obligations.
- Examine the First Supplemental Indenture (Exhibit 4.2) for the detailed calculation of the "make-whole" redemption premium.
- Confirm the Company's current liquidity position and ability to service the new 8.625% interest obligation in the context of its most recent 10-Q or 10-K.